About Angitia
Angitia is a company based in Woodland Hills (United States) founded in 2018 by Ke Huazhu. It operates as a HealthTech. Angitia has raised $406 million across 6 funding rounds from investors including Orbimed, Global Sources and Guangzhou Hi-Tech Communication Technology. Angitia offers products and services including AGA2115. Angitia operates in a competitive market with competitors including Horizon Therapeutics, AskBio, Osteal Therapeutics, Epirium Bio and ZetaGen, among others.
- Headquarter Woodland Hills, United States
- Founders Ke Huazhu
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Angitia Biopharmaceuticals
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$406 M (USD)
in 6 rounds
-
Latest Funding Round
$130 M (USD), Series D
Feb 05, 2026
-
Investors
Orbimed
& 29 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Angitia
Angitia offers a comprehensive portfolio of products and services, including AGA2115.
A bispecific antibody for treating Osteogenesis Imperfecta.
People of Angitia
Unlock access to complete
Unlock access to complete
Funding Insights of Angitia
Angitia has successfully raised a total of $406M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $130 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series D — $130.0M
- First Round First Round
- Investors Count 30
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2026 | Amount | Series D - Angitia | Valuation | Frazier Life Sciences , Venrock | |
| Dec, 2024 | Amount | Series C - Angitia | Valuation | Bain Capital Life Sciences | |
| Jan, 2024 | Amount | Series B - Angitia | Valuation | Guangzhou Hi-Tech Communication Technology |
Investors in Angitia
Angitia has secured backing from 30 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Global Sources and Guangzhou Hi-Tech Communication Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Angitia
Financial Statements - Angitia
Angitia Comparisons
Competitors of Angitia
Angitia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, AskBio, Osteal Therapeutics, Epirium Bio and ZetaGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer via mitochondrial biogenesis are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for bone regeneration are developed.
|
|
| domain | founded_year | HQ Location |
Developer of nucleic acid therapeutics for cancer and rare muscular disorders
|
Frequently Asked Questions about Angitia
Angitia was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Angitia is headquartered in Woodland Hills, United States. It is registered at Woodland Hills, California, United States.
Ke Huazhu is the current CEO of Angitia. They have also founded this company.
Angitia is a funded company, having raised a total of $406M across 6 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Aug 18, 2020.
Angitia Biopharmaceuticals is engaged in the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company addresses unmet medical needs in conditions such as Osteogenesis Imperfecta, Osteoporosis, and Degenerative Disc Disease. Solutions are developed through clinical-stage biotechnology expertise, with a commitment to improving patient outcomes in these critical health sectors.
Angitia's top competitors include Horizon Therapeutics, AskBio and ZetaGen.
Angitia offers AGA2115.
Angitia has 30 investors. Key investors include Orbimed, Global Sources, Guangzhou Hi-Tech Communication Technology, Bain Capital Life Sciences, and Yonghua Capital.